Jia-Yi Chen (Jiayi Chen)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Breast Cancer Risk

Liver Metastases

Radiation Therapy

Decision Making

Top Venues

Technology in cancer research & treatment

Journal of oncology

Nature communications

Radiation oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Xiao-Yu Wu, Mei Chen, Lu Cao, Min Li, Jia-Yi Chen
Proton Therapy in Breast Cancer: A Review of Potential Approaches for Patient Selection. Technology in cancer research & treatment 23 (2024)
Xiao-Yu Wu, Mei Chen, Lu Cao, Min Li, Jia-Yi Chen
Proton Therapy in Breast Cancer: A Review of Potential Approaches for Patient Selection. Technology in cancer research & treatment 23 (2024)
Xiao-Yu Wu, Mei Chen, Lu Cao, Min Li, Jia-Yi Chen
Proton Therapy in Breast Cancer: A Review of Potential Approaches for Patient Selection. Technology in cancer research & treatment 23 (2024)
Chu-Ying Chen, Si-Yue Zheng, Gang Cai, Cheng Xu, Rong Cai, Min Li, Kun-Wei Shen, Xiao-Song Chen, Dan Ou, Shengguang Zhao, Lu Cao, Jia-Yi Chen
Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy. Journal of oncology 2022 (2022)
Chu-Ying Chen, Si-Yue Zheng, Gang Cai, Cheng Xu, Rong Cai, Min Li, Kun-Wei Shen, Xiao-Song Chen, Dan Ou, Shengguang Zhao, Lu Cao, Jia-Yi Chen
Postoperative Radiotherapy Contributes to the Survival Benefit of Breast-Conserving Therapy over Mastectomy. Journal of oncology 2022 (2022)
Qian Zhu, Jinzhou Huang, Hongyang Huang, Huan Li, Peiqiang Yi, Jake A Kloeber, Jian Yuan, Yuping Chen, Min Deng, Kuntian Luo, Ming Gao, Guijie Guo, Xinyi Tu, Ping Yin, Yong Zhang, Jun Su, Jia-Yi Chen, Zhenkun Lou
RNF19A-mediated ubiquitination of BARD1 prevents BRCA1/BARD1-dependent homologous recombination. Nature communications 12 (1) (2021)
Gang Cai, Lu Cao, Youlia M Kirova, Yan Feng, Jia-Yi Chen
Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer. Radiation oncology (London, England) 14 (1) (2019)